louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05478044: Effect of Ascorbic Acid Final Flush on Post-operative Pain in Mandibular Molars.
Official title: Effect of Ascorbic Acid as a Final Flush on Post-operative Pain After Single Visit Root Canal Treatment for Patients With Symptomatic Irreversible Pulpits Related to Mandibular Molars: Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Post Operative Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-07-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is conducted to evaluate the effect of Ascorbic acid as a final flush on post operative pain after single visit root canal treatment in cases with symptomatic irreversible pulpits.


Eligibility criteria: Inclusion Criteria:

* Patients above 18 years old and to 60.
* Male or female.
* Patients seeking root canal treatment.
* mandibular molar teeth with symptomatic irreversible pulpits with preoperative acute or moderate pain with hot and cold stimulation with normal periapical radiographic appearance .
* healthy patient (ASA I,II).
* Patient who can understand NRS and sign informed consent.

Exclusion Criteria:

* Medically compromised patients having significant systemic disorders. (ASA III or IV).
* History of intolerance to NSAIDS.
* External root resorption.
* Internal root resorption.
* Vertical root fracture.
* Periapical lesion.
* Pregnancy.
* Use of ibuprofen in the last 12 hour.
* Bleeding disorder.
* Long term corticosteroid use.
* Mobility Grade II or III.
* Pocket depth more than 5mm.
* Previous root canal therapy.
* Non-restorability.
* TMJ problems, bruxism, clenching or traumatic occlusion.
* Inability to perceive the given instructions.

Primary outcomes:
measure: Pain intensity measured by numerical rating scale where 0= no pain, 1-3= mild pain, 4-6= moderate pain and 7-10= severe pain.
timeFrame: up to 48 hours after root canal treatment.
Secondary outcomes:
measure: If there are analgesics taken by the patient after root canal treatment and that will be measured by a questionnaire.
timeFrame: up to 48 hours.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05931744: The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis
Official title: The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis . A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Chronic Rhinosinusitis With Nasal Polyps
Keywords: CRSwNP
Intranasal steroid injection
Budesonide
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2023-07-05
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the usage of budesonide as an agent in the injection of Type 2 chronic rhinosinusitis with nasal polyps

Detailed description: this is a randomized controlled clinical trial where 3 groups with nasal polyps will be treated medically, Group A with oral corticosteroids, Group B with budesonide intrapolyp injection, Group C with placebo saline intrapolyp injection

Eligibility criteria: Inclusion Criteria:

* All patients with type 2 CRSwNP -
* elevated serum IgE \& high absolute eosinophilia
* with any grade of nasal polyps
* ages between 18 and 60 years old
* patients who didn't have any contraindications of systemic steroids

Exclusion Criteria:

* All patients with previous nasal surgeries
* All patients with cystic fibrosis, ciliary dyskinesia, antrochoanal polyp, fungal sinusitis, unilateral nasal polyps, nasal tumors,
* patients who took systemic steroids in the last 6 months before our study
* patients with any previous nasal surgery

Primary outcomes:
measure: Sino-Nasal Outcome Test "SNOT-22" Score
timeFrame: 6 months
measure: CT Lund Mackay
timeFrame: 6 months
measure: Total nasal Polyp score "TNPS"
timeFrame: 6 months
measure: Serum IgE
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Kafrelsheikh
country: Egypt
facility: Kafrelsheikh University hospital
Study officials:
References:
Clinical trial NCT02562144: A Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults
Official title: A Randomized Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Lead sponsor: Isala
Sponsor class: OTHER
First posted: 2015-09-29
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The enrolled subjects will get an intravenous cannulation in both elbows. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.

Detailed description: The enrolled subjects will get an intravenous cannulation in both elbows. The influence of the left or right-handedness is reduced by randomizing the arms of the subjects in the placebo group or xylocaine group. The subject will get before xylocaine spray is placed, the intervention-arm, one intravenous cannulation in one of the elbows, the other intravenous cannulation is placed in the other arm before placebo spray is placed, the control arm. The pain score during insertion of the cannulation, the incidence of adverse events and the success rate and degree of difficulty to place an intravenous cannulation. The subjects and the one who place the cannulations will be blinded to the treatment.

Eligibility criteria: Inclusion Criteria:

* Adults (aged 18 or older)
* Signing of the informed consent paper

Exclusion Criteria:

* Allergy for xylocaine
* Pregnancy or breast-feeding
* Peripheral neuropathy
* Analgesics in the last 24 hours
* Skin conditions (eczema, psoriasis, infection, or abrasions)
* Difficulties in verbal communication
* No intravenous access in both elbows possible (eg status after axillary dissection )

Primary outcomes:
measure: The pain score of the tested subjects during intravenous cannulation
timeFrame: A few seconds after intravenous cannulation
Secondary outcomes:
measure: Complications or adverse reactions of xylocaine spray or placebo spray
timeFrame: 5 minutes after xylocaine spray or placebo and 15 minutes after cannulation
measure: Influence of xylocaine spray in successfully placing an IV cannulation
timeFrame: Before intravenous cannulation
measure: The degree of difficulty in successfully placing an IV cannulation
timeFrame: A few seconds after intravenous cannulation
Other outcomes:
Locations:
Study officials:
affiliation: Isala Zwolle
name: Joris Datema, Drs
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06208644: Identification of Obstacles and Levers to Interdisciplinary Work in Palliative Care Units
Official title: Identification of Obstacles and Levers to Interdisciplinary Work in Palliative Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Palliative Care
Keywords: Palliative Care
Palliative Care Units
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2024-01-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Health professionals working in palliative care unit and Health students (hospital students, nurses, etc.) doing an internship in this unit.

Brief summary: Palliative care is active care delivered by a multidisciplinary team, in a global approach to the person suffering from a serious, progressive illness, in an advanced phase, with a fatal outcome. Their goal is to relieve physical pain and other symptoms, but also to take into account psychological, social and spiritual suffering.

Palliative care and support are interdisciplinary. They are aimed at the patient as an individual, their family and loved ones, at home or in an institution. Training and support for caregivers and volunteers are part of this approach.

Recent years have seen the development of teaching in the discipline both during the initial course and through continuing training actions, the latter based on the very notion of multi-professionality. But it is clear that during the initial course of health professionals, learning remains confined to professions, in silos.

It is in view of this observation that the 2015-2018 palliative care development plan in France proposed the establishment of transversal teaching, for health students, through its measures 4.1 and 4.2, lessons put in place at through local initiatives which are still underdeveloped.

It is therefore appropriate to question the methods of learning "know how to work together". This work therefore aims to reflect, through what can promote but also hinder interdisciplinary work, on the way in which health students can be taught to work in interdisciplinarity and in particular during their internships in palliative care structures


Eligibility criteria: Inclusion Criteria:

* Health professionals, all professions combined, working in palliative care units agreeing to participate in research
* Health students (hospital students, nurses, etc.) doing an internship in a palliative care unit agreeing to participate in research
* Agreeing to participate in the study

Exclusion Criteria:

* Refusal to participate in research

Primary outcomes:
measure: Review of the perception of interdisciplinarity and interdisciplinary work among staff working or doing an internship in a palliative care unit
timeFrame: Study covers the period from August 25, 2023 to October 25, 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de soins Palliatifs - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT05875844: Wrist Splint and Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
Official title: Effectiveness of Wrist Splint and Occupational Therapy to Improve Pain, Mobility and Functional Status in Patients With Wrist Drop
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Wrist-Drop
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2023-05-25
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To determine effectiveness of wrist splint and occupational therapy to improve pain, mobility and functional status in patients with wrist drop.


Eligibility criteria: Inclusion Criteria:

* • People with wrist drop

  * People between 20 to 40 years will be included (male and female)
  * Post-operative patients (nerve grafting and plastic surgery)
  * Patients with findings of nerve compression will be included

Exclusion Criteria:

* • People with nerve injuries other than radial nerve such as ulnar or median nerve

  * People suffering with other neurological disorders.
  * People who are not able to follow instructions
  * Any traumatic history
  * Diabetic patients, thyroid issues, pregnant females

Primary outcomes:
measure: DASH scale (0-100)
timeFrame: 6 Months
measure: VAS on the scale (1-10)
timeFrame: 6 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Chaudary Muhammad Akram Teaching Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT02957344: Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers
Official title: Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy Children
Keywords: health communication
Zika virus
legislation
vaccination
Child Care
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2016-11-06
Enrollment: 679
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Mothers of children 12 years of age or younger will be surveyed by email. They will be recruited from a group of women who have previously participated in a paper in-office survey at nine obstetrics/gynecology (OB/GYN) practices across the Front-Range region of Colorado. Women who completed the paper survey and provided contact information for future surveys may be contacted to participate in this survey.

Brief summary: Through an online survey, participants will be shown different visual presentations of vaccination data related to schools and child care centers. Participants will rate how important this information is when thinking about their child's health and school choice. Participants will also be asked survey questions about their knowledge of Colorado state vaccination legislation, their opinions and practices related to childhood vaccinations, and their views of a Zika virus vaccine.


Eligibility criteria: Inclusion Criteria:

* mother of a child 12 years of age or younger
* English literacy to complete the survey

Exclusion Criteria:

* respondent has a child of appropriate age but that child will not attend a school or child care center outside of the home

Primary outcomes:
measure: Survey/Questionnaire of parental knowledge and attitudes related to vaccines, schools, and child care centers.
timeFrame: On average within 2 months of survey invitation.
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: University of Colorado Denver
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Sean O'Leary, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01552044: Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis
Official title: Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Central Serous Chorioretinitis
Keywords: retina
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2012-03-13
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the effect of spironolactone on 16 patients presenting with chronic non-resolutive central serous chorioretinitis (CSCR) and to evaluate whether spironolactone can resolve sub retinal fluid in these patients.

CSCR is a major cause of visual loss in the young population. It is characterized by sub retinal fluid under the retina and retinal pigment epithelial detachments. The exact causes of the disease remain unknown but a choroidopathy has been suggested. Moreover, corticotherapy and stress are known risk factors of CSCR.

Our preclinical studies have demonstrated that the mineralocorticoid pathway could be involved in the control of choroidal blood flow.

The investigators propose to evaluate the mineralocorticoid receptors antagonist spironolactone in the treatment of CSCR.

Criteria of efficacy Endpoint: reduction of subretinal fluid ≥ 40 microns Secondary endpoint: visual acuity gain ≥ 15 EDTRS letters

Detailed description: This is a prospective placebo controlled cross over study including 16 patients

Eligibility criteria: Inclusion Criteria:

* Patient between 18 and 60 years
* CSCR affecting the macula and non-resolutive for at least 3 months
* Patients having given and signed informed consent
* Vital prognosis non engaged for the next 6 months.

Exclusion Criteria:

* Other ocular pathology
* Neovascularization,
* Diabetes
* Uveitis
* Ocular surgery in the last 3 months
* Allergy to fluorescein or indocyanine green
* Pregnancy or no contraception
* Renal or liver insufficiency
* Kaliemia ≥ 5.5 mmol/l Criteria of efficacy

Primary outcomes:
measure: Change in Central macular thickness
timeFrame: 1 and 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Hotel-Dieu of Paris
Study officials:
References:
Clinical trial NCT01844440: Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD
Official title: Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastroesophageal Reflux Disease
Keywords: GERD
tLESR
impedance
manometry
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2013-05-01
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to establish and validate High resolution manometry (HRM) criteria for the definition of transient lower esophageal sphincter relaxations (tLESRs) in gastroesophageal reflux disease (GERD) patients.

Detailed description: tLESRs represent the main mechanism of all types of reflux events. Inhibition of transient lower esophageal sphincter relaxations (tLESRs) has become one of the most relevant therapeutic objectives in patients with reflux symptoms resistant to proton pump inhibitors. HRM is the gold standard for detecting and characterizing tLESR, and could be considered as part of the pharmacological evaluation of new drugs targeting tLESRs. HRM criteria for the objective definition of tLESRs in GERD patients have to be established, as it has been done in healthy patients Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.

Eligibility criteria: Inclusion Criteria:

* Patients 18 to 75 years old
* GERD documented by :

  * Typical reflux symptoms (heartburn, regurgitations) completely responsive to PPI therapy
  * And/or erosive esophagitis or Barrett's esophagus at endoscopy
  * And/or positive pH 24h monitoring (acid exposure time \> 5% or positive symptom association indices)
* Possibility of easily positioned transnasal catheter
* Patients covered by social security
* Subjects must provide written, free and informed consent

Exclusion Criteria:

* Pregnant or lactating women
* History of digestive or thoracic surgery (except appendicectomy)
* Patients unable to stop PPI therapy for 7 days
* Subjects unable to provide written consent, including adult under guardianship and emergency situation
* Simultaneous participation in another study

Primary outcomes:
measure: tLESRs characteristics
timeFrame: Inclusion (Day 0)
measure: Reflux underlying mechanisms
timeFrame: Inclusion (Day 0)
Secondary outcomes:
Other outcomes:
Locations:
city: Bordeaux
country: France
facility: Service d'hépato-gastroentérologie et oncologie digestive
city: Lyon
country: France
facility: Service d'Exploration Fonctionnelle Digestive
city: Nantes
country: France
facility: Institut des Maladies de l'Appareil Digestif (IMAD)
Study officials:
affiliation: University Hospital, Bordeaux
name: Frank ZERBIB, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06334640: Sleeping Quality and Chronic Ocular Diseases
Official title: L'Impatto Del Sonno Nelle Patologie Croniche Oculari
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sleep Disorder
Lead sponsor: Istituto Auxologico Italiano
Sponsor class: OTHER
First posted: 2024-03-28
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatients attending our Institution for scheduled visits/examinations

Brief summary: To assess the impact of sleep quality on chronic eyes diseases

Detailed description: In this study 3 questionnaires will be distributed to outpatients attending the routine examinations : the Pittsburgh, the Berlin and the Epworth tests These questionnaires, once completed, will then be collected to be then transformed into digital files for the appropriate statistical evaluations and the drafting of the results and conclusions.

Eligibility criteria: Inclusion Criteria:

* Patients with macular degeneration or glaucoma or
* Healthy volunteers

Exclusion Criteria:

- Patients with other ocular disorders

Primary outcomes:
measure: Proportion of sleep disorders in patients and healthy volunteers
timeFrame: At enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Milan
country: Italy
facility: Istituto Auxologico Italiano IRCCS
Study officials:
References:
Clinical trial NCT02377440: Effects of ACEI on Bone Turnover
Official title: Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bone Turnover Status in Hypertensive Patients
Keywords: ACE inhibitor
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: National Aeronautics and Space Administration (NASA)
First posted: 2015-03-03
Enrollment: 32
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 60 patients (30 men and 30 women) 45 years or older will be recruited at designated outpatient clinics and randomly allocated 1:1 to receive ACEI vs. a non RAS-related antihypertensive medication.

Brief summary: The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications


Eligibility criteria: Inclusion Criteria:

* at least 45 years of age
* a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control
* able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment).

Exclusion Criteria:

* younger than 45 years of age
* a diagnosis of metabolic bone disease
* a diagnosis of osteoporosis or use of medication to treat osteoporosis
* a diagnosis of diabetes mellitus, or renal insufficiency, or cancer
* history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.

Primary outcomes:
measure: Change in serum CTX levels in pg/mL
timeFrame: baseline, 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: Nahid Rianon, MD
state: Texas
city: Houston
country: United States
facility: University of Texas Medical School at Houston
state: Texas
Study officials:
References: